What it's for (Indications)
- This fixed-dose combination medication, containing isoniazid, rifampicin, and ethambutol, is primarily indicated for the initial intensive phase treatment of active pulmonary and extrapulmonary tuberculosis caused by susceptible strains of Mycobacterium tuberculosis.
- It is a cornerstone of first-line antitubercular regimens, designed to rapidly reduce bacterial load, prevent the emergence of drug resistance, and achieve sputum smear conversion.
- Its use is typically guided by susceptibility testing to ensure efficacy against the infecting strain.
- This combination is crucial for facilitating patient adherence to complex multi-drug regimens and improving treatment outcomes in newly diagnosed tuberculosis cases, contributing significantly to public health efforts in disease control.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | Dosage of this fixed-dose combination must be carefully individualized based on the patient's body weight, typically administered once daily. For adults, a common regimen involves specific mg/kg dosing for each component, often leading to a daily intake of approximately 300 mg isoniazid, 600 mg rifampicin, and 800-1200 mg ethambutol. The exact tablet strength and number of tablets to be taken daily will vary by manufacturer and specific formulation. This intensive phase treatment usually spans two months, followed by a continuation phase with a different regimen. Strict adherence to the prescribed dosage and duration is paramount to prevent treatment failure and the development of drug-resistant tuberculosis. Dosage adjustments may be necessary in patients with renal or hepatic impairment, and administration with food may improve tolerability. Healthcare providers must supervise administration to ensure compliance. |
Safety & Warnings
Common Side Effects
- The use of this antitubercular combination can lead to a range of side effects, some of which are serious and require immediate medical attention.
- Common side effects include gastrointestinal disturbances (nausea, vomiting, abdominal pain, anorexia), headache, dizziness, and rash.
- More concerning adverse reactions include hepatotoxicity (elevated liver enzymes, hepatitis, jaundice) which can be severe and potentially fatal, particularly with isoniazid and rifampicin.
- Ethambutol is associated with optic neuritis, manifesting as blurred vision, visual field defects, or red-green color blindness, which can be irreversible if not detected early.
- Isoniazid can cause peripheral neuropathy, especially in malnourished, diabetic, or alcoholic patients, often mitigated by pyridoxine supplementation.
- Other serious side effects may include flu-like syndrome, thrombocytopenia, leukopenia, hemolytic anemia, acute renal failure, drug-induced lupus erythematosus, and severe cutaneous adverse reactions (e.
- g.
- , Stevens-Johnson Syndrome).
- Rifampicin can also cause harmless reddish-orange discoloration of urine, sweat, tears, and other body fluids, which patients should be counselled about.
Serious Warnings
- Black Box Warning: SEVERE AND SOMETIMES FATAL HEPATOTOXICITY: The combination of isoniazid and rifampicin carries a significant risk of severe and sometimes fatal hepatitis, especially during the first few months of treatment. The risk is dose-related, age-related (increasing with age), and significantly elevated in patients with pre-existing liver disease, daily alcohol consumption, or concomitant use of other hepatotoxic drugs. Patients must be educated on the signs and symptoms of hepatitis (e.g., fatigue, weakness, malaise, anorexia, nausea, vomiting, dark urine, or yellowing of the skin or eyes) and instructed to seek immediate medical attention if these occur. Liver function tests must be monitored at baseline and periodically throughout treatment, and the medication should be promptly discontinued if significant liver injury is suspected. IRREVERSIBLE OPTIC NEURITIS: Ethambutol can cause optic neuritis, potentially leading to irreversible vision loss. This adverse effect is typically dose and duration dependent, manifesting as blurred vision, central scotoma, or loss of red-green color discrimination. Patients must undergo thorough ophthalmological examination, including visual acuity and color vision testing, at baseline and regularly during treatment. Discontinuation of ethambutol is mandatory at the first sign of visual disturbance. Failure to detect and address optic neuritis early can result in permanent blindness. This drug combination must be used with extreme caution under strict medical supervision, with vigilant monitoring for these severe adverse reactions.
- Patients receiving this fixed-dose combination require rigorous monitoring due to several serious potential adverse effects.
- **Hepatotoxicity** is a significant concern, particularly with isoniazid and rifampicin.
- Baseline and periodic monitoring of liver function tests (LFTs) is essential.
- Treatment should be discontinued if signs or symptoms of hepatitis develop (e.
- g.
- , dark urine, jaundice, persistent nausea/vomiting, unexplained fatigue) or if LFTs elevate significantly.
- **Optic neuritis** caused by ethambutol necessitates baseline and regular visual acuity and color discrimination tests.
- Patients must be instructed to report any visual changes immediately; irreversible vision loss can occur.
- **Peripheral neuropathy** due to isoniazid is a risk, especially in patients predisposed to neuropathy, and prophylactic pyridoxine (Vitamin B6) is often recommended.
- **Drug-drug interactions** are extensive, particularly with rifampicin, a potent inducer of cytochrome P450 enzymes.
- This can significantly reduce the efficacy of many co-administered drugs, including oral contraceptives, anticoagulants, antiretrovirals, corticosteroids, and antidiabetics.
- Careful review of all concomitant medications is crucial.
- Use with caution in patients with renal impairment, diabetes, HIV infection, or alcohol use disorder, as these conditions may increase the risk of adverse effects or require dose adjustments.
- Adherence to the full prescribed course is vital to prevent relapse and resistance development.
How it Works (Mechanism of Action)
This combination leverages the distinct mechanisms of three potent antitubercular agents to achieve synergistic bactericidal and bacteriostatic effects against Mycobacterium tuberculosis. **Isoniazid (INH)**, a prodrug, is activated by the mycobacterial catalase-peroxidase enzyme KatG. Its active form inhibits the synthesis of mycolic acids, essential components of the mycobacterial cell wall, leading to bactericidal action. **Rifampicin (RMP)** acts by binding to the beta-subunit of bacterial DNA-dependent RNA polymerase, thereby inhibiting RNA synthesis and protein transcription. This results in potent bactericidal activity against rapidly multiplying and dormant bacilli. **Ethambutol (EMB)** inhibits arabinosyl transferases, enzymes crucial for the biosynthesis of arabinogalactan, a polysaccharide component of the mycobacterial cell wall. This disrupts cell wall formation, making it primarily bacteriostatic, and importantly, prevents the emergence of resistance to other drugs in the regimen. The combined action of these drugs targets different vital processes in the bacteria, ensuring a broad attack and significantly reducing the likelihood of resistance development.
Commercial Brands (Alternatives)
No other brands found for this formula.